Physician profile
Eric Carandang
NPI 1629010210
$3,932.15
in general payments reported to CMS, 2019-2025
32 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.98 · 2022: $471 · 2023: $1,181 · 2024: $771 · 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,354 · Education: $84.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,354.10 |
| Education | $84.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,106.93 | 2021-2025 | |
| Janssen Biotech, INC. | $532.62 | 2022-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $486.46 | 2022-2024 | Xifaxan, Trulance, Plenvu |
| Qol Medical, LLC | $245.27 | 2024-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $215.15 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.62 | 2022-2025 | Entyvio |
| Ardelyx, INC. | $114.48 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $113.69 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $107.43 | 2022-2023 | Linzess |
| Ipsen Biopharmaceuticals, INC | $103.02 | 2024-2025 | Iqirvo |
| Celgene Corporation | $87.83 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $80.15 | 2022-2025 | Ocaliva |
| Celltrion USA INC. | $62.14 | 2024 | Zymfentra, Vegzelma |
| Pfizer INC. | $45.76 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $43.55 | 2023-2025 | Givlaari |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $40.21 | 2023 | Clenpiq, Rebyota |
| Phathom Pharmaceuticals, INC. | $35.45 | 2025 | Voquezna |
| Lilly USA, LLC | $34.83 | 2023-2025 | Omvoh |
| Daiichi Sankyo INC. | $31.13 | 2022 | |
| Gilead Sciences, INC. | $30.84 | 2022-2025 | |
| Organon LLC | $30.57 | 2025 | |
| Bausch & Lomb Americas INC. | $30.53 | 2022 | |
| Vivus LLC | $29.39 | 2023 | Pancreaze, Qsymia |
| Amgen INC. | $27.57 | 2022 | |
| Fresenius Kabi USA, LLC | $24.84 | 2023 | Idacio |
| Biocon Biologics INC | $24.59 | 2025 | Yesintek |
| Braintree Laboratories, INC. | $23.83 | 2023 | Sutab |
| Evoke Pharma, INC. | $16.75 | 2024 | |
| Merck Sharp & Dohme LLC | $16.48 | 2022 | |
| Aimmune Therapeutics, INC. | $16.13 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $15.92 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $14.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Carandang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.